Desarrollar terapias contra el VIH de próxima generación
A high priority of NIH-sponsored research is to develop next-generation HIV therapies. Despite the advent of simplified daily combination treatments which provide sustained viral suppression, there is still a need to identify new long-acting medications with fewer side effects in parallel with the development of novel delivery and testing technologies to improve efficacy of and adherence to treatment. To achieve this goal, ERC-CFAR investigators are applying basic sciences research and drug discovery strategies to identify new druggable targets that prevent viral assembly or virus-host interactions, develop new preclinical drug animal models and develop broadly neutralizing antibodies as a new sustained anti-HIV treatment. Listed below are NIH-funded studies by our ERC-CFAR Investigators researching strategies to develop Next-Generation HIV therapies.
| Investigator | Institution | NIH Grant | Title |
|---|---|---|---|
| Paul Bieniasz | Rockefeller | R01AI157809 | Host protein targets of HIV-1 vpr in gene expression, cell cycle and innate immunity |
| Paul Bieniasz | Rockefeller | R01AI050111 | RNA protein interactions in HIV-1 replication |
| Paul Bieniasz. | Rockefeller | R37AI064003 | Discovery and mechanism of antiretroviral factors |
| Felipe Díaz-Griffero | Einstein | R01AI087390 | Modulation of retroviral uncoating by cellular factors |
| Felipe Díaz-Griffero | Einstein | R01AI150455 | Regulation of SAMHD1 antiviral activity |
| Harris Goldstein | Einstein | R01AI145024 | Novel biologics designed to mobilize HIV-specific CTL for sustained HIV remission |
| Ganjam Kalpana | Einstein | R21AI156932 | Structure-based design of stapled peptides to target Gag-Pol and INI1 interaction to block assembly |
| Denis Nash | CUNY SPH | R34MH126809 | Assessing Perceptions and Preferences around Long-acting Injectables (APPLI) in the Ryan White HIV/AIDS Program |